Skip to main content
Home
FULL MENU Close Menu
Home
Home

Mark D. Pearlman, MD

Article

Progress in breast cancer screening over the past 50 years: A remarkable story, but still work to do

Author:
Mark D. Pearlman, MD

Expert perspective on the myriad factors that play a role in breast cancer screening recommendations and the guidelines to consider when engaging...

  • Read More

Article

Late-onset recurrence in breast cancer: Implications for women’s health clinicians in survivorship care

Author:
Mark D. Pearlman, MD

Data show that late-onset recurrence is more likely among patients with an initial tumor size >2 cm, lymph node–positive disease, and hormone...

  • Read More

Article

It’s not time to abandon routine screening mammography in average-risk women in their 40s

Author:
Mark D. Pearlman, MD

Results of a new mammography screening study inform us that routine breast cancer risk assessment to facilitate patient...

  • Read More

Article

Should supplemental MRI be used in otherwise average-risk women with extremely dense breasts?

Author:
Mark D. Pearlman, MD

Recent data show that supplemental MRI screening in women with extremely dense breasts and negative screening mammograms decreases the rate of...

  • Read More

Article

Should breast cancer screening guidelines be tailored to a patient’s race and ethnicity?

Author:
Dana M. Scott, MD
Mark D. Pearlman, MD

Yes. Because women of minor ity races/ethnicities have an earlier age of onset of breast cancer (45 to 50 years) compared with...

  • Read More

Article

How does oral contraceptive use affect one’s risk of ovarian, endometrial, breast, and colorectal cancers?

Author:
Dana M. Scott, MD
Mark D. Pearlman, MD

Oral contraceptives (OCs) are associated with a decreased risk of ovarian and endometrial cancers across multiple modifiable...

  • Read More

Article

Does hormonal contraception increase the risk of breast cancer?

Author:
Dana Scott, MD
Mark D. Pearlman, MD

These experts analyze the data from a recent large study and provide counseling points for your patients

  • Read More

Article

Breast cancer screening: Is the controversy of benefits versus harms resolved?

Author:
Mark D. Pearlman, MD

Researchers recently described which national mammography screening strategy most effectively reduced breast cancer mortality and resulted in most...

  • Read More

Article

Does extending aromatase-inhibitor use from 5 to 10 years benefit menopausal women with hormone-positive breast cancer?

Author:
Mark D. Pearlman, MD

In terms of improving the 5-year disease-free survival (DFS) rate, yes, according to results of a randomized study that compared extended...

  • Read More

News

Based on interval cancer rates, which women with dense breasts are most likely to benefit from supplemental imaging?

Author:
Mark D. Pearlman, MD

The authors of this prospective study involving more than 350,000 patients observed high interval cancer rates for women with 5-year breast cancer...

  • Read More

News

Is supplemental ultrasonography a valuable addition to breast cancer screening for women with dense breasts?

Author:
Mark D. Pearlman, MD

The benefit is small and the cost is high, according to this comparative modeling study.

  • Read More

News

Which women are most likely to die from breast cancer—those screened annually starting at age 40, biennially starting at age 50, or not at all?

Author:
Mark D. Pearlman, MD

Most deaths from breast cancer occur in women who are unscreened, according to this review of medical records and death data from two large...

  • Read More

News

UPDATE ON BREAST HEALTH

Author:
Mark D. Pearlman, MD
Jennifer L. Griffin Miller, MD, MPH

A look at findings from the estrogen-alone arm of the WHI, chemoprophylaxis for high-risk women, and fertility preservation for young breast...

  • Read More

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close